Christopher H. Van Buren

Davis Polk advised BiondVax Pharmaceuticals Ltd. in connection with its registered at-the-market offering of shares of its American depositary shares for up to a maximum offering price of …

Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…

Davis Polk advised the representative of the underwriters in connection with a registered offering of $150 million aggregate principal amount of PDC Energy, Inc.’s 5.750% senior notes due…

Davis Polk advised the representative of the several underwriters in connection with the SEC-registered offering of 30,675,000 shares of common stock of Plug Power Inc. for approximately …

Davis Polk advised Automatic Data Processing, Inc. (“ADP”) in connection with its SEC-registered offering of $1 billion aggregate principal amount of 1.250% senior notes due 2030.  …

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Livent Corporation of $225 million aggregate principal amount of its 4.125%…

Davis Polk advised the joint book-running managers in connection with a Rule 144A/Regulation S notes offering by Sands China Ltd. of $800 million of its 3.800% senior notes due 2026…

Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering of 5,000,000 shares of common stock of TransMedics Group, Inc…

Davis Polk advised the joint book-running managers in connection with a registered offering by Eli Lilly and Company of $1.0 billion aggregate principal amount of its 2.250% notes due 2050…

Davis Polk advised the underwriter in connection with the $59.9 million secondary offering of 2,678,049 shares of common stock of TriState Capital Holdings, Inc. by selling shareholders LM…